Patient Guide to Support Services

Seattle Genetics

SeaGen Secure
855-473-2873
(855-4SECURE)

Seattle Genetics SeaGen Secure is a comprehensive reimbursement program providing personalized services to patients and helpful assistance for practices utilizing Adcetris (brentuximab vedotin) therapy. Adcetris is a CD30-directed antibody drug conjugate that is indicated for several types of lymphoma (Table).

SeaGen Secure Assistance Programs

The SeaGen Secure program is available to patients who are underinsured (with commercial or government-funded insurance) and to uninsured patients. SeaGen Secure assists in conducting a benefits investigation for each patient to determine their coverage.

Depending on their coverage status, patients may have 1 of the following options:

  • Underinsured patients who need help with their coinsurance may be eligible for the SeaGen Secure Commercial Assistance Program or may be referred to an independent foundation for assistance
  • For insured patients whose insurance does not cover Adcetris, SeaGen Secure will help with their claims appeal process. Patients whose appeal is rejected may be eligible for patient assistance
  • Uninsured patients may be eligible for the SeaGen Secure Patient Assistance Program.

Eligibility

To be eligible for the SeaGen Secure Assistance Program, patients must:

  • Permanently live in the United States
  • Meet the income and diagnosis guidelines.

Application & Enrollment

To avail oneself of SeaGen Secure patient assistance and reimbursement support services, the Enrollment Form must first be completed. Enrollment forms can be submitted electronically via the website.

Completed forms can also be faxed to 855-557-2480 or e-mailed to This email address is being protected from spambots. You need JavaScript enabled to view it.. Benefits investigation results will be faxed within 48 hours.

Prescribers are required to provide their information, provide the patient’s information and diagnosis, including an ICD-10 diagnosis code, indicate whether the patient has received a transplant and if the transplant was autologous or allogeneic, and indicate previous regimens that have been used. Patient information, including health insurance information, employer information, and gross annual family household income, must be provided.

Oncology Nurse Advocate

SeaGen Secure connects patients and caregivers with an experienced Oncology Nurse Advocate. The Oncology Nurse Advocate will provide support to help address patient concerns while they are receiving treatment, and will relay important patient information to your practice.

The Oncology Nurse Advocate will work with your patient to identify concerns before they become obstacles, and offer solutions to help address specific needs; provide ongoing support throughout the treatment experience; and offer referrals to advocacy organizations for emotional support, transportation assistance, peer-to-peer connection programs, and resources for balancing work and cancer.

Patients will speak with the same Oncology Nurse Advocate every time they call SeaGen Secure.

Table Seattle Genetics Oncology Drug

Drug
Indications
Patient support programs

Drug
Adcetris (brentuximab vedotin)
Indication
Untreated stage III or IV classical Hodgkin lymphoma, in combination with doxorubicin, vinblastine, and dacarbazine; classical Hodgkin lymphoma ­­ at high risk for relapse or progression after autologous hematopoietic stem-cell transplant consolidation; classical Hodgkin lymphoma, after failure of ASCT, or after ≥2 multiagent chemotherapy regimens if ineligible for transplant; untreated systemic anaplastic large-cell lymphoma or other CD30-expressing peripheral T-cell lymphoma; systemic anaplastic large-cell lymphoma after failure of ≥1 multiagent chemotherapy regimens; primary cutaneous T-cell lymphoma, or CD30-expressing mycosis fungoides after systemic therapy
Patient support program

ASCT indicates autologous stem-cell transplant.

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: